Imagyn sells surgical needle line to Surgical Supply:
This article was originally published in Clinica
Imagyn Medical Technologies is to sell its surgical needle product line to Surgical Supply for $7.65 million. Newport Beach, California-based Imagyn will use the proceeds from the sale to reduce debt. The company is disposing of certain non-core assets and hopes to reach agreement concerning further sales during this quarter. Separately, Imagyn plans to begin commercial shipment of International Isotopes' brachytherapy seed, IsoStar, for which it has exclusive distribution rights.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.